STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Molecular Biotechnological Research Original Research

In silico analysis of Abrus precatorius L. as a potential agonist of PPARγ : A novel approach to the treatment of diabetes

  1. Grace R. Michael* Department of Bioinformatics, BioNome,

Abstract

Diabetes mellitus is a chronic disorder that is characterized by a lack of insulin secretion by the pancreas or a defect in insulin action, or both. If diabetes is not controlled, over time it can cause damage to blood vessels and nerves, leading to life-threatening complications such as, kidney damage, heart disease and vision impairment. It can also weaken the immune system, making patients more prone to infection. Although treatments for diabetes has improved over the past few decades, mortality rates due to diabetes and its complications have been on the rise. Moreover, some hyperglycemic agents have been shown to induce irreversible side effects. Therefore, there is an urgent need to explore alternative therapeutic treatments to combat this disease. Peroxisome proliferator-activated receptor gamma (PPARγ) is an important protein that helps regulate glucose levels in the blood. This study explores the potential modulation of PPARγ by phytochemical compounds. In many countries including India, medicinal plants have been used as anti-diabetic agents. Abrus precatorius Linn is an important herb commonly known as rosary pea and abundantly found throughout India. A.precatorius can be used to treat a variety of diseases as various parts of the plants have different pharmacological activity, such as anti-diabetic, anti-oxidative, anti- inflammatory, anti-microbial and neuro-protective effects. The phytochemicals were extracted from the Indian Medicinal Plants, Phytochemistry and Therapeutics(IMPPAT). PyRx, an in-silico tool was then used to perform molecular docking simulations in order to find the lead compounds. The phytochemical compounds kaempferol, carvacrol, abrine, thymol methyl ether, and thymol which had the highest binding affinities with PPARγ were selected for further in silico analysis and pharmacological evalution was carried out on the basis of ADMET properties, which was performed in ADMETlab. The compound kaempferol showed the highest binding affinity with PPARγ. Its molecular interaction with PPARγ was captured on Biovia Discovery Studio Visualizer.

Keywords

References (43)

  1. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005 May;26(2):19-39. PMID: 16278749; PMCID: PMC1204764.
  2. Shendurse, A. M., and C. D. Khedkar. "Glucose: properties and analysis." Encyclopedia of food and health 3 (2016): 239-247.
  3. CHEATHAM B, KAHN CR. Insulin Action and the Insulin Signaling Network*. Endocrine Reviews. 1995;16(2):117-142. doi:10.1210/edrv-16-2-117
  4. International Diabetes Federation. IDF Diabetes Atlas, 11th edn. Brussels, Belgium: 2025. Available at: https://diabetesatlas.org
  5. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2016;66(2):241-255. doi:10.2337/db16-0806
  6. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontiers in Endocrinology. 2017;8. doi:10.3389/fendo.2017.00006
  7. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology. 2014;4. doi:10.3389/fphar.2013.00177
  8. Gordon A, Buch Z, Baute V, Coeytaux R. Use of Ayurveda in the Treatment of Type 2 Diabetes Mellitus. Global Advances in Health and Medicine. 2019;8. doi:10.1177/2164956119861094
  9. Dafar S, M. R. B, A. M. N, D. P. D, S. S. R. A Review on Phytochemical and Pharmacological Study of Herbal Medicinal Plant: Abrus precatorious. International Journal of Newgen Research in Pharmacy & Healthcare. 2023:161-173. doi:10.61554/ijnrph.v1i2.2023.31
  10. Qian H, Wang L, Li Y, Wang B, Li C, Fang L, et al. The traditional uses, phytochemistry and pharmacology of Abrus precatorius L.: A comprehensive review. Journal of Ethnopharmacology. 2022;296:115463. doi:10.1016/j.jep.2022.115463
  11. Garaniya, Narendra, and Atul Bapodra. "Ethno botanical and Phytophrmacological potential of Abrus precatorius L.: A review." Asian Pacific journal of tropical biomedicine 4 (2014): S27-S34
  12. Carvalho MVD, Gonçalves-de-Albuquerque CF, Silva AR. PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases. International Journal of Molecular Sciences. 2021;22(2):805. doi:10.3390/ijms22020805
  13. Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future Cardiology. 2017;13(3):279-296. doi:10.2217/fca-2017-0019
  14. Agha Zeeshan Mirza, Ismail I. Althagafi, Hina Shamshad,Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications,European Journal of Medicinal Chemistry,Volume 166,2019,Pages 502- 513,ISSN02235234,https://doi.org/10.1016/j.ejmech.2019.01.067.(https://www.scienced irect.com/science/article/pii/S022352341930087X)
  15. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochemical Pharmacology. 2014;92(1):73-89. doi:10.1016/j.bcp.2014.07.018
  16. Dao NA, Vu TD, Chu DT. Bioinformatics in Drug Discovery. Advances in Bioinformatics. 2024:239-248. doi:10.1007/978-981-99-8401-5_11
  17. Xia X. Bioinformatics and Drug Discovery. Current Topics in Medicinal Chemistry. 2017;17(15):1709-1726. doi:10.2174/1568026617666161116143440
  18. Pinzi L, Rastelli G. Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences. 2019;20(18):4331. doi:10.3390/ijms20184331
  19. Chaudhary KK, Mishra N (2016) A Review on Molecular Docking: Novel Tool for Drug Discovery. JSM Chem 4(3): 1029
  20. Mohanraj, K., Karthikeyan, B.S., Vivek-Ananth, R.P. et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics. Sci Rep 8, 4329 (2018).
  21. Kim S. Getting the most out of PubChem for virtual screening. Expert Opinion on Drug Discovery. 2016;11(9):843-855. doi:10.1080/17460441.2016.1216967
  22. Burley SK, Berman HM, Duarte JM, Feng Z, Flatt JW, Hudson BP, et al. Protein Data Bank: A Comprehensive Review of 3D Structure Holdings and Worldwide Utilization by Researchers, Educators, and Students. Biomolecules. 2022;12(10):1425. doi:10.3390/biom12101425
  23. Bhagyashree L. Jejurikar, Sachin H. Rohane. Drug Designing in Discovery Studio. Asian J. Research Chem. 2021; 14(2):135-138. doi:10.5958/0974-4150.2021.00025.0 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2021-14-2-8
  24. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 2017;7(1). doi:10.1038/srep42717
  25. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research. 2021;49(W1):W5-W14. doi:10.1093/nar/gkab255
  26. Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opinion on Drug Discovery. 2020;15(12):1473-1487. doi:10.1080/17460441.2020.1798926
  27. https://doi.org/10.1093/bioinformatics/18.11.1548
  28. Bastaki S. Diabetes mellitus and its treatment. International Journal of Diabetes and Metabolism. 2019:111-134. doi:10.1159/000497580
  29. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes. Diabetes. 2005;54(suppl_2):S97-S107. doi:10.2337/diabetes.54.suppl_2.s97
  30. Confederat, L. U. M. I. N. I. Ț. A., et al. "Side effects induced by hypoglycaemic sulfonylureas to diabetic patients-a retrospective study." Farmacia 64.5 (2016): 674-9.
  31. Rizos C, Elisaf M, Mikhailidis D, Liberopoulos E. How safe is the use of thiazolidinediones in clinical practice? Expert Opinion on Drug Safety. 2008;8(1):15-32. doi:10.1517/14740330802597821
  32. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012 Nov 9;8(5):899-906. doi:10.5114/aoms.2012.31621. Epub 2012 Nov 7. PMID: 23185202; PMCID: PMC3506243.
  33. Katara P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Network Modeling Analysis in Health Informatics and Bioinformatics. 2013;2(4):225-230. doi:10.1007/s13721-013-0039-5
  34. Lai X, Wang X, Hu Y, Su S, Li W, Li S. Editorial: Network Pharmacology and Traditional Medicine. Frontiers in Pharmacology. 2020;11. doi:10.3389/fphar.2020.01194
  35. Periferakis A, Periferakis K, Badarau IA, Petran EM, Popa DC, Caruntu A, et al. Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications. International Journal of Molecular Sciences. 2022;23(23):15054. doi:10.3390/ijms232315054
  36. Chen M, Xiao J, El-Seedi HR, Woźniak KS, Daglia M, Little PJ, et al. Kaempferol and atherosclerosis: From mechanism to medicine. Critical Reviews in Food Science and Nutrition. 2022;64(8):2157-2175. doi:10.1080/10408398.2022.2121261
  37. Imran M, Salehi B, Sharifi-Rad J, Aslam Gondal T, Saeed F, Imran A, et al. Kaempferol: A Key Emphasis to Its Anticancer Potential. Molecules. 2019;24(12):2277. doi:10.3390/molecules24122277
  38. Alam W, Khan H, Shah MA, Cauli O, Saso L. Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing. Molecules. 2020;25(18):4073. doi:10.3390/molecules25184073
  39. Dong X, Zhou S, Nao J. Kaempferol as a therapeutic agent in Alzheimer’s disease: Evidence from preclinical studies. Ageing Research Reviews. 2023;87:101910. doi:10.1016/j.arr.2023.101910
  40. Dabeek WM, Marra MV. Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans. Nutrients. 2019;11(10):2288. doi:10.3390/nu11102288
  41. Yang Y, Chen Z, Zhao X, Xie H, Du L, Gao H, et al. Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review. Frontiers in Endocrinology. 2022;13. doi:10.3389/fendo.2022.990299
  42. Li Y, Mai Y, Qiu X, Chen X, Li C, Yuan W, et al. Effect of long-term treatment of Carvacrol on glucose metabolism in Streptozotocin-induced diabetic mice. BMC Complementary Medicine and Therapies. 2020;20(1). doi:10.1186/s12906-020-02937-0
  43. Hoca M, Becer E, Vatansever HS. Carvacrol is potential molecule for diabetes treatment. Archives of Physiology and Biochemistry. 2023;130(6):823-830. doi:10.1080/13813455.2023.2288537